Identifying good responders to glucose lowering therapy in type 2 diabetes: Implications for stratified medicine

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Jones, Angus G ^a   Shields, Beverley M ^a   Hyde, Christopher J ^a   Henley, William E ^a   Hattersley, Andrew T ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; CREATININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROSPECTIVE STUDY; TREATMENT OUTCOME; AGONISTS; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; METABOLISM; MIDDLE AGED; TIME FACTOR;

BLOOD GLUCOSE; C-PEPTIDE; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84908565964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111235     Document Type: Article

References (16)

1. National Institute of Clinical Excellence (UK) (2009) Guideline CG87 - Type 2 diabetes: the management of type 2 diabetes.
2. Fleiss JL (1981) Statistical methods for rates and proportions. John Wiley, new York.
3. DeFronzo RA, Stonehouse AH, Han J, Wintle ME (2010) Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabetic medicine: a journal of the British Diabetic Association 27: 309-317.
4. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE (2006) Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes care 29: 2137-2139.
5. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D (2012) Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes, obesity & metabolism 14: 228-233.
6. Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC et al. (2012) Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes care 35: 955-958.
7. Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A et al. (2013) Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes, metabolic syndrome and obesity: targets and therapy 6: 123-129.
8. Penformis, Martinez S, Madani S, Charpentier G, Eschwege E et al. (2013) Diabetes duration and background diabetes therapies in predicting liraglutide treatment response: data from post-marketing EVIDENCE study. Diabetologia 56, Supplement 1.
9. Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S (2012) Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract.
10. Hall GC, McMahon AD, Dain MP, Wang E, Home PD (2013) Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabetic medicine: a journal of the British Diabetic Association 30: 681-686.
11. Yanez ND 3rd, Kronmal RA, Shemanski LR (1998) The effects of measurement error in response variables and tests of association of explanatory variables in change models. Stat Med 17: 2597-2606.
12. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM (2005) When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol 162: 267-278.
13. Robinson LD JN (1991) Some surprising results about covariate adjustment in logistic regression models. Int Stat Rev 59: 227-240.
14. Gale EA, Beattie SD, Hu J, Koivisto V, Tan MH (2007) Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes care 30: 2989-2992.
15. Hopewell JC, Parish S, Offer A, Link E, Clarke R et al. (2013) Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. European heart journal 34: 982-992.
16. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E et al. (2004) Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension 43: 1202-1207.